Screener
Supernus Pharmaceuticals SUPN Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating loss | (8,332) | (10,256) |
| Other income (expense) | ||
| Interest and other income, net | 2,382 | 4,425 |
| Total other income (expense), net | 2,382 | 4,425 |
| Loss before income taxes | (5,950) | (5,831) |
| Income tax expense (benefit) | (3,657) | 5,996 |
| Net loss | $(2,293) | $(11,827) |
| Loss per share |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's other income (expense)?
- Supernus Pharmaceuticals (SUPN) reported other income (expense) of $2.38M in Q1 2026.
- How has Supernus Pharmaceuticals's other income (expense) changed year-over-year?
- Supernus Pharmaceuticals's other income (expense) decreased by 46.2% year-over-year, from $4.43M to $2.38M.
- What is the long-term trend for Supernus Pharmaceuticals's other income (expense)?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's other income (expense) has grown at a 0.8% compound annual growth rate (CAGR), from -$12.85M to $13.25M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Supernus Pharmaceuticals's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude